MGDL:TASEMigdal Insurance & Financial Holdings Ltd. Analysis
Data as of 2026-06-14 - not real-time
ILA 1,833.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Migdal (MGDL) trades around 1,833 ILA, well below its DCF‑derived fair value of roughly 20,300 ILA, indicating a sizable upside potential. The stock’s trailing P/E of 10.2 is markedly lower than the industry average of 16.8, reinforcing the undervaluation narrative. Revenue growth of 12 % and a solid ROE of 20 % demonstrate robust earnings momentum. However, free cash flow is negative despite a healthy operating cash flow, reflecting heavy capital deployment. The company holds an impressive cash pile of 153 B ILA, which cushions the high debt‑to‑equity ratio of about 80 %. Dividend yield sits at a modest 0.49 % with a payout ratio effectively at zero, raising questions about dividend sustainability. Overall, the fundamentals suggest a value‑oriented investment with growth attributes.
Technically, the price sits below the 20‑day (1,877 ILA) and 50‑day (1,903 ILA) moving averages, and the MACD is in a bearish configuration, signaling short‑term downside pressure. RSI at 45.7 and a neutral trend direction indicate the stock is not yet oversold. Volatility is elevated at 45.6 % over the past 30 days, while beta of 0.34 points to low systematic risk. Support around 1,694 ILA and resistance near 2,042 ILA define a relatively wide trading range. The market sentiment is in “Extreme Greed” territory, which could temporarily inflate prices. Given the stable volume and low liquidity risk, the stock remains tradable without major execution concerns. Investors should balance the attractive valuation against the short‑term technical weakness and modest dividend outlook.
Technically, the price sits below the 20‑day (1,877 ILA) and 50‑day (1,903 ILA) moving averages, and the MACD is in a bearish configuration, signaling short‑term downside pressure. RSI at 45.7 and a neutral trend direction indicate the stock is not yet oversold. Volatility is elevated at 45.6 % over the past 30 days, while beta of 0.34 points to low systematic risk. Support around 1,694 ILA and resistance near 2,042 ILA define a relatively wide trading range. The market sentiment is in “Extreme Greed” territory, which could temporarily inflate prices. Given the stable volume and low liquidity risk, the stock remains tradable without major execution concerns. Investors should balance the attractive valuation against the short‑term technical weakness and modest dividend outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD with price below short‑term SMAs
- High 30‑day volatility
- Proximity to support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap vs DCF
- Strong cash reserves offsetting debt
- Revenue growth and solid ROE
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Resilient insurance business model
- Low beta indicating defensive profile
- Sustained earnings profitability
Key Metrics & Analysis
Financial Health
Revenue Growth12.10%
Profit Margin15.10%
P/E Ratio10.2
ROE20.34%
ROA0.86%
Debt/Equity80.37
P/B Ratio1.9
Op. Cash FlowILA4.6B
Free Cash FlowILA-19782500352
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI45.7
SupportILA 1,694.00
ResistanceILA 2,042.00
MA 20ILA 1,877.60
MA 50ILA 1,902.60
MA 200ILA 1,553.31
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair ValueILA 20,345.92
GradeUndervalued
TypeBlend
Dividend Yield0.49%
Risk Assessment
Beta0.34
Volatility45.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.